U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C6F14
Molecular Weight 338.0418
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PERFLEXANE

SMILES

FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F

InChI

InChIKey=ZJIJAJXFLBMLCK-UHFFFAOYSA-N
InChI=1S/C6F14/c7-1(8,3(11,12)5(15,16)17)2(9,10)4(13,14)6(18,19)20

HIDE SMILES / InChI

Molecular Formula C6F14
Molecular Weight 338.0418
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: http://www.ncbi.nlm.nih.gov/books/NBK25382/

Perflexane is a contrast agent for ultrasound Imaging. The mechanism of action of perflexane is an ultrasound contrast activity. Perflexane is a fluorinated hydrocarbon and gaseous substance used as an imaging contrast agent in the echocardiogram. After administration in microsphere form, perflexane increases ultrasound reflectivity of blood. This leads to an improvement of ultrasound signaling. Perflexane-lipid microspheres (AFO150) is a preparation of perfluorocarbon (PFC)-based micro bubbles it was approved by the Food and Drug Administration in 2002 for clinical use in echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border. However, AFO150 is not currently available for clinical applications.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
IMAGENT

Approved Use

in subjects with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border

Launch Date

2004
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
26.3 ng/mL
20 μg/kg bw single, intravenous
dose: 20 μg/kg bw
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PERFLEXANE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
11.3 ng × h/mL
20 μg/kg bw single, intravenous
dose: 20 μg/kg bw
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PERFLEXANE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
5.7 h
20 μg/kg bw single, intravenous
dose: 20 μg/kg bw
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PERFLEXANE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
5.3 h
20 μg/kg bw single, intravenous
dose: 20 μg/kg bw
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PERFLEXANE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Effects of vaporized perfluorocarbon on pulmonary blood flow and ventilation/perfusion distribution in a model of acute respiratory distress syndrome.
2001 Dec
A possible mechanism of naproxen-induced lipid peroxidation in rat liver microsomes.
2001 Jul
Carbomethoxychlorocarbene: spectroscopy, theory, chemistry and kinetics.
2001 Jun 27
Fluorous triphasic reactions: transportative deprotection of fluorous silyl ethers with concomitant purification.
2001 Oct 17
AFO 150. Imagent, Imavist.
2002
Improvements in the ultrasonic contrast of targeted perfluorocarbon nanoparticles using an acoustic transmission line model.
2002 Jan
Changes in pulmonary function and oxygenation during application of perfluorocarbon vapor in healthy and oleic acid-injured animals.
2002 Jun
Phase-vanishing reactions that use fluorous media as a phase screen. Facile, controlled bromination of alkenes by dibromine and dealkylation of aromatic ethers by boron tribromide.
2002 Nov 6
A new experimental protocol for intrazeolite photooxidations. The first product-based estimate of an upper limit for the intrazeolite singlet oxygen lifetime.
2002 Sep 25
Ultrasound-mediated cavitation thresholds of liquid perfluorocarbon droplets in vitro.
2003 Sep
Liquid crystalline behavior of a semifluorinated oligomer.
2004 Dec 8
[Reduction in the aggressiveness of ventilation by inhalation of perfluorohexane after therapy of oleic acid-induced respiratory failure].
2004 Feb
Noninvasive estimation of the pressure gradient across stenoses using sonographic contrast: in vitro validation.
2004 May
Effect of oxygenated perfluorocarbons on isolated rat pancreatic islets in culture.
2005
Comparison of different inhalational perfluorocarbons in a rabbit model of acute lung injury.
2005 Jan-Feb
Effects of perfluorohexan vapor on gas exchange, respiratory mechanics, and lung histology in pigs with lung injury after endotoxin infusion.
2005 Sep
Cyclic variation in ultrasonic myocardial integrated backscatter is due to phasic changes in the number of patent myocardial microvessels.
2006 Aug
Comparative effects of vaporized perfluorohexane and partial liquid ventilation in oleic acid-induced lung injury.
2006 Feb
Investigating perfluorohexane particles with high-frequency ultrasound.
2006 Jan
Rate enhancement of Diels-Alder reactions in aqueous perfluorinated emulsions.
2006 Nov 23
Raman microspectroscopy/imaging study on phase-vanishing processes of fluorous biphase systems in microchannel-microheater chips.
2006 Oct
Positive end-expiratory pressure at minimal respiratory elastance represents the best compromise between mechanical stress and lung aeration in oleic acid induced lung injury.
2007
Phagocytosis of ultrasound contrast agent microbubbles by Kupffer cells.
2007 Feb
Exposure of an adult population to perfluorinated substances using duplicate diet portions and biomonitoring data.
2007 Nov 15
Structure and depletion at fluorocarbon and hydrocarbon/water liquid/liquid interfaces.
2008 Aug 15
Leukocyte antibacterial functions are not impaired by perfluorocarbon exposure in vitro.
2008 Jul
Influence of collection solvent on permeation of di-n-octyl disulfide through nitrile glove material.
2008 Mar 1
Solvation of halogens in fluorous phases. Experimental and simulation data for F2, Cl2, and Br2 in several fluorinated liquids.
2008 May 29
Perfluorohexane-loaded macrophages as a novel ultrasound contrast agent: a feasibility study.
2008 Sep
The multi-vicinal fluoroalkane motif: an examination of 2,3,4,5-tetrafluorohexane stereoisomers.
2008 Sep 7
Reverse water-in-fluorocarbon microemulsions stabilized by new polyhydroxylated nonionic fluorinated surfactants.
2009 Aug 18
Environmental hazards and health risk of common liquid perfluoro-n-alkanes, potent greenhouse gases.
2009 Feb
Polyfluoroalkyl chemicals in the serum and milk of breastfeeding women.
2009 Jun
A novel and stable "two-hit" acute lung injury model induced by oleic acid in piglets.
2009 Mar 30
Perfluorinated compounds in delivering women from south central Vietnam.
2009 Nov
Gels from a semifluorinated n-alkane in fluorinated solvents as a probe for intermolecular interactions.
2009 Nov 1
A new method for the preparation of monoporous hollow microspheres.
2010 Apr 6
Pretreatment with perfluorohexane vapor attenuates fMLP-induced lung injury in isolated perfused rabbit lungs.
2010 Aug
Controlling the thickness of hollow polymeric microspheres prepared by electrohydrodynamic atomization.
2010 Aug 6
Delivery of water-soluble drugs using acoustically triggered perfluorocarbon double emulsions.
2010 Dec
Sonochemical synthesis of liquid-encapsulated lysozyme microspheres.
2010 Feb
Phospholipid-coated gas bubble engineering: key parameters for size and stability control, as determined by an acoustical method.
2010 Feb 2
Permeation of a metalworking fluid through a latex glove under field use conditions.
2010 Jan
Systemic perfluorohexane attenuates lung injury induced by lipopolysaccharide in rats: the role of heme oxygenase-1.
2010 Jan-Feb
Female scent signals enhance the resistance of male mice to influenza.
2010 Mar 1
Pilot study of vaporization of perfluorohexane during high-frequency oscillatory ventilation in experimental acute lung injury.
2010 Nov
Effects of perfluorohexane vapor in the treatment of experimental lung injury.
2010 Oct
Patents

Sample Use Guides

The recommended dose is 0.00625 mL/kg (0.125 mg/kg) administered as a single intravenous bolus over a period of not less than 10 seconds and immediately followed by a saline flush. Imagent (The active moiety, the microsphere, comprises two critical components: perflexane, the gaseous component, and DMPC, the lipid membrane component) must be used within 30 minutes of reconstitution.
Route of Administration: Intravenous
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:59:36 GMT 2023
Edited
by admin
on Fri Dec 15 15:59:36 GMT 2023
Record UNII
FX3WJ41CMX
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PERFLEXANE
INN   MART.   ORANGE BOOK   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
PERFLEXANE [ORANGE BOOK]
Common Name English
PERFLUOROHEXANE [MI]
Common Name English
AF-0150
Code English
PERFLEXANE [MART.]
Common Name English
PERFLUOROHEXANE [INCI]
Common Name English
perflexane [INN]
Common Name English
Tetradecafluorohexane
Systematic Name English
AF0150
Code English
HEXANE, TETRADECAFLUORO-
Systematic Name English
Perflexane [WHO-DD]
Common Name English
PERFLEXANE [VANDF]
Common Name English
PERFLUOROHEXANE
INCI   MI  
INCI  
Official Name English
PERFLEXANE [USAN]
Common Name English
Classification Tree Code System Code
NDF-RT N0000010259
Created by admin on Fri Dec 15 15:59:36 GMT 2023 , Edited by admin on Fri Dec 15 15:59:36 GMT 2023
CFR 21 CFR 173.342
Created by admin on Fri Dec 15 15:59:36 GMT 2023 , Edited by admin on Fri Dec 15 15:59:36 GMT 2023
NDF-RT N0000175864
Created by admin on Fri Dec 15 15:59:36 GMT 2023 , Edited by admin on Fri Dec 15 15:59:36 GMT 2023
NCI_THESAURUS C1937
Created by admin on Fri Dec 15 15:59:36 GMT 2023 , Edited by admin on Fri Dec 15 15:59:36 GMT 2023
Code System Code Type Description
MESH
C078626
Created by admin on Fri Dec 15 15:59:36 GMT 2023 , Edited by admin on Fri Dec 15 15:59:36 GMT 2023
PRIMARY
CHEBI
39427
Created by admin on Fri Dec 15 15:59:36 GMT 2023 , Edited by admin on Fri Dec 15 15:59:36 GMT 2023
PRIMARY
RXCUI
1540828
Created by admin on Fri Dec 15 15:59:36 GMT 2023 , Edited by admin on Fri Dec 15 15:59:36 GMT 2023
PRIMARY RxNorm
EVMPD
SUB33239
Created by admin on Fri Dec 15 15:59:36 GMT 2023 , Edited by admin on Fri Dec 15 15:59:36 GMT 2023
PRIMARY
DAILYMED
FX3WJ41CMX
Created by admin on Fri Dec 15 15:59:36 GMT 2023 , Edited by admin on Fri Dec 15 15:59:36 GMT 2023
PRIMARY
WIKIPEDIA
PERFLUOROHEXANE
Created by admin on Fri Dec 15 15:59:36 GMT 2023 , Edited by admin on Fri Dec 15 15:59:36 GMT 2023
PRIMARY
SMS_ID
100000126369
Created by admin on Fri Dec 15 15:59:36 GMT 2023 , Edited by admin on Fri Dec 15 15:59:36 GMT 2023
PRIMARY
PUBCHEM
9639
Created by admin on Fri Dec 15 15:59:36 GMT 2023 , Edited by admin on Fri Dec 15 15:59:36 GMT 2023
PRIMARY
FDA UNII
FX3WJ41CMX
Created by admin on Fri Dec 15 15:59:36 GMT 2023 , Edited by admin on Fri Dec 15 15:59:36 GMT 2023
PRIMARY
DRUG BANK
DB09531
Created by admin on Fri Dec 15 15:59:36 GMT 2023 , Edited by admin on Fri Dec 15 15:59:36 GMT 2023
PRIMARY
MERCK INDEX
m8541
Created by admin on Fri Dec 15 15:59:36 GMT 2023 , Edited by admin on Fri Dec 15 15:59:36 GMT 2023
PRIMARY Merck Index
HSDB
7871
Created by admin on Fri Dec 15 15:59:36 GMT 2023 , Edited by admin on Fri Dec 15 15:59:36 GMT 2023
PRIMARY
CAS
355-42-0
Created by admin on Fri Dec 15 15:59:36 GMT 2023 , Edited by admin on Fri Dec 15 15:59:36 GMT 2023
PRIMARY
INN
7917
Created by admin on Fri Dec 15 15:59:36 GMT 2023 , Edited by admin on Fri Dec 15 15:59:36 GMT 2023
PRIMARY
EPA CompTox
DTXSID7046548
Created by admin on Fri Dec 15 15:59:36 GMT 2023 , Edited by admin on Fri Dec 15 15:59:36 GMT 2023
PRIMARY
ChEMBL
CHEMBL1200607
Created by admin on Fri Dec 15 15:59:36 GMT 2023 , Edited by admin on Fri Dec 15 15:59:36 GMT 2023
PRIMARY
USAN
KK-122
Created by admin on Fri Dec 15 15:59:36 GMT 2023 , Edited by admin on Fri Dec 15 15:59:36 GMT 2023
PRIMARY
DRUG CENTRAL
3429
Created by admin on Fri Dec 15 15:59:36 GMT 2023 , Edited by admin on Fri Dec 15 15:59:36 GMT 2023
PRIMARY
ECHA (EC/EINECS)
206-585-0
Created by admin on Fri Dec 15 15:59:36 GMT 2023 , Edited by admin on Fri Dec 15 15:59:36 GMT 2023
PRIMARY
NCI_THESAURUS
C47663
Created by admin on Fri Dec 15 15:59:36 GMT 2023 , Edited by admin on Fri Dec 15 15:59:36 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY